-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Castration-resistant prostate cancer (CRPC) patients still progress after the initial continuous androgen deprivation treatment.
Recently, researchers evaluated the therapeutic effect of 177Lu-PSMA-617 on mCRPC patients
This study is an international, public, phase III trial.
immunity
A total of 831 patients participated in the study, and the baseline characteristics of the patients were similar
Compared with standard care, in the 177Lu-PSMA-617 group, imaging-based progression-free survival (median progression-free survival: 8.
Differences in progression-free survival and overall survival between groups
Differences in progression-free survival and overall survival between groupsFor patients with advanced PSMA-positive metastatic castration-resistant prostate cancer, 177Lu-PSMA-617 targeted radiotherapy can significantly improve the patient's progression-free survival rate and overall survival rate
For patients with advanced PSMA-positive metastatic castration-resistant prostate cancer, 177Lu-PSMA-617 targeted radiotherapy can significantly improve the patient’s progression-free survival rate and overall survival rate.
Original source:
Oliver Sartor et al.
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Leave a message here